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Background. Malathion 0.5% has been the most prescribed pediculicide in the United Kingdom for around 10 years, and is
widely used in Europe and North America. Anecdotal reports suggest malathion treatments are less effective than formerly,
but this has not been confirmed clinically. This study was designed to determine whether malathion is still effective and if 4%
dimeticone lotion is a more effective treatment for head louse infestation. Methodology/Principal Findings. We designed
this study as an assessor blinded, randomised, controlled, parallel group trial involving 58 children and 15 adults with active
head louse infestation. Each participant received two applications 7 days apart of either 4% dimeticone lotion, applied for
8 hours or overnight, or 0.5% malathion liquid applied for 12 hours or overnight. All treatment and check-up visits were
conducted in participants’ homes. Cure of infestation was defined as no evidence of head lice after the second treatment.
Some people were found free from lice but later reinfested. Worst case, intention to treat, analysis found dimeticone was
significantly more effective than malathion, with 30/43 (69.8%) participants cured using dimeticone compared with 10/30
(33.3%) using malathion (p,0.01, difference 36.4%, 95% confidence interval 14.7% to 58.2%). Per protocol analysis showed
cure rates of 30/39 (76.9%) and 10/29 (34.5%) respectively. Irritant reactions were observed in only two participants, both
treated with malathion. Conclusions/Significance. We concluded that, although malathion liquid is still effective for some
people, dimeticone lotion offers a significantly more effective alternative treatment for most people. Trial Registration.
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INTRODUCTION
In a previous study [1] we demonstrated 4% dimeticone lotion was
effective to eliminate head louse infestation from 70% of cases and
equivalent in activity to 0.5% phenothrin liquid. Dimeticone lotion
is now a licensed medicinal over the counter product in the UK. A
later study [2] comparing ‘‘bug-busting’’ (Community Hygiene
Concern, London) with a single application of insecticide found
malathion 17% successful. 0.5% malathion liquid is a treatment of
choice for many Primary Care Trusts and minor ailment schemes
and is a first choice insecticide recommendation on the Clinical
Knowledge Summaries (formerly PRODIGY) online guidance for
head louse treatment. [3]
We have been aware that resistance to malathion in head lice has
been spreading in the UK since it was first identified from Brighton
in 1995. [4] Malathion resistance is now found in most parts of the
country [5–7] but was not identified in a recent study conducted in
Wales to investigate resistance to insecticides there. [8]
We have performed a controlled trial, analysed by intention to
treat, comparing the efficacy of two applications 7 days apart of
either 4% dimeticone lotion or 0.5% malathion liquid. The
treatment interval of 7 days complies with the marketing
authorisation approval for 4% dimeticone lotion and the
recommendations set out in the British National Formulary. [9]
METHODS
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Participants
Participants were recruited via local newspaper and radio
advertising. Families responding to advertising were sent a Partic-
ipant Information Booklet (PIB) by post. Those who then wished
to enrol telephoned again to request a home visit, usually within
24 hours. Trained investigators used a standard protocol to
examine participants for head lice using a plastic detection comb
(‘‘PDC’’, KSL Consulting, Denmark). If lice were found, and the
participant was eligible, a signed consent and assent procedure was
followed. Other household members were offered examination
and invited to join if eligible.
All enrolled participants provided baseline data on age, gender,
hair characteristics, and previous pediculicide use. The lower age
limit was 6 months in conformity with the licence for both
products; there was no upper limit. Treatments and assessments
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participation. Ineligible infested household members were pro-
vided with 4% dimeticone lotion.
Participants were required to confirm their availability for the
duration of the study (14 days following the first treatment) in
order to be included in the study. Exclusion criteria were:
N Known sensitivity to any ingredients in the treatments.
N Secondary bacterial infection of the scalp (e.g. impetigo) or any
long term scalp condition other than head louse infestation (e.g.
psoriasis of the scalp).
N Use of other head louse products within the previous two
weeks.
N Use of hair bleach, colour, or permanent wave products, within
the previous four weeks.
N Treatment with the antibiotics Co-Trimoxazole or Trimetho-
prim within the previous four weeks, or taking such a course at
the time of enrolment.
N Pregnant or nursing mothers.
N Participation in another clinical study within 1 month before
entry to this study.
N Previous participation in this clinical study. [10]
Ethics
Prospective participants who wished to participate reported that
they understood the purpose and requirements of the study
outlined in the PIB and provided written consent. Parents or
guardians provided written consent for children below 16 years,
who also gave written or verbal assent witnessed by the parent/
guardian. Ethical approval was granted by Hertfordshire 1
Research Ethics Committee (EudraCT 2006-004136-73).
The study was conducted in conformity with the principles of
the Declaration of Helsinki and of European Union Directive
2001/20/EC.
Interventions
Dimeticone 4% lotion was supplied in 150 ml bottles (HedrinH 4%
lotion, Thornton & Ross Ltd, Huddersfield, UK) and 0.5%
malathion liquid in 200 ml bottles (Derbac-M liquid, SSL In-
ternational, Manchester, UK). Both products were applied to dry
hair, using enough to thoroughly moisten the hair and scalp.
Investigatorsapplied theproductsevenlythroughthehairusing their
fingers.Treatmentswereappliedtothe fullhairlength andleftto dry
naturally. [1] The same regimen was repeated 7 days later.
Participants were provided with non-medicated, conditioner free
shampoo to ensure all treatments were washed off using the same
preparation. Carers were advised of the earliest time treatment
should be removed, usually the following morning, and asked not to
use louse combs, other form of head louse treatment during
participation, and not to divulge the treatment to assessors to
maintain blinding. Most participants had previously used one or
both preparations so it was impossible to blind them to treatment.
However, when asked about the most recent previous treatment it
was found only five had used a malathion product, between
2 months and 3 years previously, four of whom were allocated
dimeticone and one malathion. Compliance with the protocol was
assessed by retrospective questionnaire at each assessment.
Objectives
The study was designed to compare the efficacy of 4% dimeticone
lotion with 0.5% malathion liquid with sufficient power to be able
to determine if activity against head lice of either product was
superior to the other.
Outcomes
The primary outcome measure was elimination of head lice using
two applications of treatment. All participants were examined by dry
detection combing, using the ‘‘PDC’’ comb, on days 2, 6, 9, and 14
after the first application of treatment unless they were lost to follow
up. Examinations were performed using the comb systematically
across the whole scalp. Examinations on days 2, 6, and 9 were
limited to 2–3 strokes of the comb on each section, intended to
provide diagnostic snapshot data of the status of infestation, because
more prolonged combing could have become an additional
intervention. A more extensive examination was made on day 14
to try to ensure no lice were present. ‘‘Cure’’ was defined as no lice
after the second application of treatment, on days 9 and 14.
Previous experience showed a high risk of reinfestation after
cure. [1] Knowledge of family circumstances helped identify some
reinfestation risks but for statistical purposes we arbitrarily
specified criteria for reinfestation as a) no adult lice or third stage
nymphs found after the first treatment; and b) on days 9 or 14, no
more than two adult lice or third stage nymphs and no younger
nymphs found during combing. We acknowledge these criteria
could give false outcomes either way but from use over several
studies we believe they address the issue of reinfestation without
presenting an unreasonably optimistic view of the product efficacy.
Any participant not fitting the cure or reinfestation after cure
criteria was categorised as a treatment failure.
Sample size
A sample size of 31 per group was estimated to have at least 80%
power to detect (with 95% confidence) a difference of 35%
between the success rates for 4% dimeticone lotion and 0.5%
malathion liquid, based on a 70% success rate for dimeticone 4%
lotion and evidence suggesting lower success rates with 0.5%
malathion liquid, of about 19%–35%. [1,2,11] The planned
sample sizes of 34 per group made some allowance for drop out.
Randomization—Allocation concealment
Treatments were randomised using a computer generated list in
balanced blocks of 10. Allocation was by inclusion of instruction
sheets in numbered sealed envelopes issued in batches of ten to
each investigator. A duplicate set was made in the event individual
code breaking was required. At enrolment treatment was allocated
using the next available number held by the investigator. As
randomisation was by individual, household members could
receive different treatments. In the event, 73 participants were
treated. After the completion of the study, an administrative error
had occurred whereby the wrong treatment instructions were
included in some of the envelopes. This meant that seven
participants originally scheduled to have 0.5% malathion in the
randomisation scheme were actually allocated dimeticone 4%.
This was discovered during analysis when it was found the
individually numbered bottles allocated to some participants did
not match the treatment group expected from the randomisation
schedule. We knew what treatment a participant had received
because their study number and initials were written on the bottle
label by the investigator giving treatment. The result was 43
participants were given 4% dimeticone and 30 participants were
given 0.5% malathion. Because this error did not compromise
blinding of either treatment allocation by investigators in the field,
or the assessors assigned to perform the checkups, the viability of
the study was not considered to have been impaired, particularly
Dimeticone for Head Lice
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some investigators using only part of their allocation of numbered
envelopes. The power to detect a 35% difference with these group
sizes was actually very similar to that for the original design.
Blinding
This study was single blinded because the physical forms of the
products are sufficiently different for double blinding to be
impractical. Most participants had used one or both preparations
previously so it was impossible to blind them to the treatment
being used. Different investigators from those applying treatment,
blinded to the allocation, performed assessments using ‘‘PDC’’
louse detection combs. Lice found during assessments were
removed and fixed to the case record using clear tape. These
were later examined under a microscope by another investigator,
also blinded to treatment, to determine their developmental stage
and if mature, their gender.
Statistical methods
For presence/absence variables, Fisher exact tests were used.
Differences in success rates between the treatments were
quantified by the 95% confidence interval, calculated using
a normal approximation to the binomial distribution.
For graded or semi-continuous variables, Kruskal-Wallis
analysis of variance was used. As there were only two groups,
this was equivalent to using the Mann-Whitney U test.
RESULTS
Participant flow
73 people from 32 families received dimeticone lotion (43) or
malathion liquid (30) and 68 (93.2%) participants (39 dimeticone,
29 malathion) completed the trial (Figure 1). There were 4
withdrawals from the dimeticone group: 1 dropped out after one
follow up for family reasons, as did the single drop out from the
malathion group. Three others from the dimeticone group failed
to complete the study, not keeping any appointments after the first
assessment on day 2. These were treated as cases lost to follow up.
All other participants had complete data sets, with two treatments
given 7 days apart and post treatment assessments conducted on
days 2, 6, 9, and 14 after the first treatment.
Recruitment
The study was conducted between October and December 2006
when consent to participate was obtained for 58 children aged 1 to
13 and 15 adults.
Baseline data
There was no significant difference between the groups in respect
of age, gender, intensity of infestation, hair length, thickness
(density), degree of curl, or whether dry/greasy (Table 1). Hair
characteristics may influence the quantity of treatment required or
ease of application, e.g. dry hair and closely spaced (thick) hair
both require more product than greasy or thin (widely spaced or
sparse) hair and can increase the difficulty of spreading some
products evenly over the hair.
Outcomes and estimation
Post treatment examinations found 25 cures and 5 cases of
reinfestation after cure with dimeticone and 9 and 1 respectively
for malathion. If the 5 drop outs were taken as treatment failures
(worst case analysis) the data provided positive outcomes of 30/43
(69.8%) for dimeticone and 10/30 (33.3%) for malathion with
a significant difference of 36.4% (14.7% to 58.2%, p,0.01). Per
protocol population positive outcomes were 30/39 (76.9%) for
Figure 1. CONSORT flowchart of participants through the study
doi:10.1371/journal.pone.0001127.g001
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significant (p,0.001) difference of 42.4% (20.7% to 64.2%).
The advantage of dimeticone over malathion was found in all
the data subgroups analysed (apart from those experiencing
adverse events), those showing statistically significant differences
being shown in Table 2. The most marked difference between the
treatments was for participants with thick hair, where the rate of
cure was only 1/7 (14.3%) for 0.5% malathion liquid as against
11/11 (100.0%) for 4% dimeticone lotion (p,0.001), which may
be a reflection of the greater difficulty of spreading the malathion
treatment evenly through thick hair.
Ancillary analyses
Analysis for an alternative worst case endpoint, in which re-
infestation was counted as a failure, would have given success rates
of 25/43 (58.1%) for 4% dimeticone and 9/30 (30.0%) for 0.5%
malathion, with the difference in rates estimated as 28.1% (6.1%
to 50.2%). This difference was less significant (p,0.05) than when
cases of reinfestation were included.
We considered the possibility that the incorrectly randomised
participants may have shown a difference of response from the rest
of the participants. We found the intention to treat cure rate 4/7
(57%) and the per protocol rate 4/6 (67%) do not differ markedly
from the overall response to 4% dimeticone. Details of the
outcomes for this sub-group are available as supporting in-
formation; see Table S1.
We also checked the effect of different treatments given to
members of a family group. Of 32 households taking part, 22 had
more than one participant, and 10 families received either only
dimeticone or only malathion. Four others had members on
different treatments but all people in these households were either
cured or treatment failures. Variation in response to the two
treatments could be found in only 8 households and the outcomes
of those treatments are shown in Table 3. Only these households
could effectively contribute to a test of treatment difference, which
limited the power to detect a difference. Nevertheless a significantly
(p,0.01) higher success rate was found for 4% dimeticone.
Dimeticone has not been considered to prevent eggs from
hatching whereas malathion has always been thought ovicidal. We
examined lice collected on days 2 and 6 for first and second stage
nymphs. We found a non-significant (p=0.28) difference for
inhibition of egg hatching, with no nymphs hatched after the first
treatment on 21/43 (49%) participants with dimeticone and 10/30
(33%) with malathion, a difference of 16% (27% to 38%).
Laboratory tests show dimeticone to be completely pediculici-
dal, with no recovery, provided lice have adequate contact with
the product. Consequently, a reasonable expectation would be
that all lice are killed by an adequate treatment, with any nymphs
Table 2. Comparison of rates of positive outcome by
treatment and data subgroup
......................................................................
Data subgroup 4% dimeticone 0.5% malathion
n/N % n/N % p
All participants 30/43 69.8 10/30 33.3 ,0.01
Sex -
males 7/9 77.8 1/3 33.3 NS
females 23/34 67.7 9/27 33.3 ,0.05
Infestation -
light 12/14 85.7 7/11 63.6 NS
moderate 11/18 61.1 2/10 20.0 ,0.1
heavy 7/11 63.6 1/9 11.1 ,0.05
Hair thickness -
fine 2/4 50.0 3/7 42.9 NS
medium 17/28 60.7 6/16 37.5 NS
thick 11/11 100.0 1/7 14.3 ,0.001
Hair curl -
straight 17/26 65.4 5/17 29.4 ,0.05
wavy or curly 13/17 76.5 5/13 38.5 ,0.1
Hair type -
dry 3/3 100.0 1/2 50.0 NS
normal 27/40 67.5 9/28 32.1 ,0.01
Adverse events seen -
no 27/38 71.1 4/21 19.1 ,0.001
yes 3/5 60.0 6/9 66.7 NS
Other family member in study -
no 5/5 100.0 2/5 40.0 NS
yes 25/38 65.8 8/25 32.0 ,0.05
doi:10.1371/journal.pone.0001127.t002
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Table 1. Baseline demographic characteristics of participants
(ITT)
......................................................................
Data subgroup 4% dimethicone 0.5% malathion
(n = 43) (n = 30)
Age in years:
range 1 to 48 3 to 48
mean 13.8 12.8
median 8 9.5
Gender: number of participants (%) number of participants
(%)
male 9 (20.9) 3 (10.0)
female 34 (79.1) 27 (90.0)
Infestation:
light 14 (32.6) 11 (36.7)
medium 18 (41.9) 10 (33.3)
heavy 11 (25.6) 9 (30.0)
Hair length:
close cropped 4 (9.3) 1 (3.3)
above ears 4 (9.3) 2 (6.7)
ears to shoulders 11 (25.6) 6 (20.0)
below shoulders 24 (55.8) 21 (70.0)
Hair thickness:
fine 4 (9.3) 7 (23.3)
average 28 (65.1) 16 (53.3)
thick 11 (25.6) 7 (23.3)
Hair curl:
straight 26 (60.5) 17 (56.7)
wavy 14 (32.6) 9 (30.0)
curly 3 (7.0) 4 (13.3)
Hair oiliness:
dry 3 (7.0) 2 (6.7)
normal 40 (93.0) 28 (93.3)
doi:10.1371/journal.pone.0001127.t001
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However, we found 9 cases categorised as failures in the
dimeticone lotion group, for which we compared the outcomes
and relationship to other participants. These data indicate two
cases due to reinfestation from within the family, and two cases
where lice were still present from day 2. The rest were all due to
failure to kill eggs, with delayed hatching in some cases. Details of
the outcomes for this sub-group are available as supporting
information; see Table S2. As we found only a few nymphs we
could not say whether these eggs were delayed in their
development by the action of the treatment, i.e. they took longer
than normal to hatch, or whether this was because some eggs
inherently take longer to hatch.
Questionnaires showed investigators rated 4% dimeticone easier
to apply (p,0.01), and easier (p,0.01) and quicker (p,0.1) to
work into the hair. The participants rated the products feeling
similar after application, but dimeticone as less odorous (p,0.001),
easier to wash out (p,0.05) and leaving the hair feeling softer
when dried (p,0.05). Both products were non-irritant to the
carers’ hands and generally left the hair easy to comb. Those given
dimeticone were significantly more inclined to use the product
again than those using malathion (97% vs 31%, p,0.001)
Adverse events
The safety evaluation found 5 adverse events in 43 participants
using dimeticone and 9 in 30 people using malathion. There were
no serious adverse events. Details of the adverse events are
available as supporting information; see Table S3. No difference
was seen between groups in number of adverse events, severity of
adverse events, relationship to study treatments, or action taken
regarding them (no participant had treatment interrupted for an
adverse event). The two participants with treatment related events
were both in the malathion group. Both experienced itching or
irritation of the scalp or neck during the treatment.
DISCUSSION
Interpretation
We have found that 4% dimeticone lotion is superior in efficacy to
0.5% malathion liquid using two applications a week apart, and
dimeticone was at least as effective (70%) as previously.[1]
Additionally, using exploratory analyses, we found a non-
significant trend suggesting 4% dimeticone lotion is more ovicidal
than 0.5% malathion liquid, and more active against louse eggs
than previously thought. However, the small sample size may have
been a source of imprecision so further investigation of the ovicidal
effect is required.
Generalizability
This is the second study investigating activity of 4% dimeticone
lotion with the primary outcome showing the same efficacy as
obtained previously (70%). [1] The positive outcome for 0.5%
malathion achieved using two applications was nearly twice the
efficacy achieved by Hill et al. [2] using a single application and
close to our estimation based on published data. We believe that
these are true representations of the current activity of the
preparations when used correctly, both products having been used
with equal thoroughness, although the malathion product was
slightly more difficult to apply. Therefore, we refute the suggestion
made by the London New Drugs Group [12] that in our earlier
study we applied dimeticone more rigorously because it was not
possible to blind application of the products, leading to bias. [1] If
that were true, it is unlikely the 0.5% phenothrin liquid
comparator would have demonstrated a greater efficacy (75%)
than dimeticone, especially as phenothrin has been shown to have
low efficacy in other studies. [13,14]
The difference in treatment outcomes may be attributable to
resistance to malathion. It is possible that these results may not be
generalizable to all malathion preparations as it is believed
alcoholic malathion products may have greater potency and the
terpenoids included in some alcoholic lotions contribute towards
the activity of the product. [13,15,16] However, recent ex vivo data,
using lice collected from the same community as our study group
and then exposed to insecticide in vitro, suggest that head lice have
developed resistance to terpenoids and that alcoholic 0.5%
malathion lotions are no more effective than the 0.5% malathion
aqueous liquid used in our study. In that work we immersed
batches of lice in either alcoholic or aqueous malathion products
as previously described [15] and observed the effects over 2 hours.
Lice treated using alcoholic 0.5% malathion with terpenoids
showed only 23% mortality compared with 47% for those exposed
to the aqueous product. In 1995, at the time resistance to
malathion was first identified, similar tests showed 100% kill using
alcoholic malathion and over 90% using the aqueous preparation.
All lice tested ex vivo in the same way but using dimeticone were
immobilised without recovery within 2 minutes (Brunton ER,
Burgess IF, personal communication). Consequently, we conclude
that 4% dimeticone lotion is likely to prove more reliably effective
than malathion products in current consumer use.
We found a similar low incidence of treatment related adverse
events to previously. For dimeticone this was a matter of avoiding
fluid flowing near to eyes. With 0.5% malathion we did find two
cases of scalp stinging where louse bites appeared irritated by the
product possibly attributable to the cetyl stearyl alcohol (Lanette
wax SX) component. However, the incidence was lower than with
0.5% phenothrin liquid, [1] which has the same vehicle but with
addition of diethylene glycol and dimethyl phthalate, both of
which have the potential to irritate. Nevertheless, even the low
incidence of irritation with 0.5% malathion liquid, which contains
less cetyl stearyl alcohol than most conditioners, indicates that this
material applied to louse bitten skin can exacerbate the itching
resulting from infestation.
Overall evidence
Previously we experienced problems with reinfestation, which we
presumed originated from other household members unable to
Table 3. Treatment outcome in households with different
outcomes for individuals using different treatments
......................................................................
Family Number of participants Treatment outcome
Dimeticone Malathion
Total Dimeticone Malathion Cure Failure Cure Failure
106 3 1 2 1 0 0 2
107 3 1 1 2 0 0 1
115 6 4 2 4 0 0 2
116 3 1 2 1 0 0 2
1 1 7 43 1 2 * 1 01
120 2 1 1 1 0 0 1
1 2 2 43 1 1 * 2 10
134 3 1 2 1 0 1 1
*Cases of reinfestation after cure
doi:10.1371/journal.pone.0001127.t003
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of reinfestation were classified as treatment failures. In this study
we addressed this issue, by enrolment of young siblings and
offering treatment to non-participants. Contrary to expectation we
did not reduce the recorded rate of reinfestation. Previously 6/127
(5%) positive treatment outcomes using dimeticone were classified
as reinfestation after cure compared with 5/43 (12%) in this study.
Since 3 of the 5 cases were in households where reinfestation could
not have occurred it appears the risk of reinfestation from outside
the family, and the control of the study, may be greater than
between siblings.
Similarly we identified apparent cases of more extensive
reinfestation amongst the treatment failure group. In one case
this also appeared to come from outside the family. However, the
majority of treatment failures were due to one or two nymphs that
had apparently hatched after day 8, raising questions about how
long head louse eggs take to hatch. This issue has been discussed
by numerous authors [see 17] but we know of no published
experimental data relating specifically to head lice (not clothing/
body lice) maintained at scalp temperature (approximately 34–36u
Celsius) and the only data we have seen are in a PhD thesis that
shows skin temperature enables head louse eggs to hatch in 6–
7 days.[18] Consequently, instructions for pediculicides vary from
country to country, often based on in vitro clothing/body louse data
that may not be an appropriate comparison. Furthermore
instructions are often vague, suggesting a second treatment after
7–10 or 7–12 days, which places a considerable burden of
judgement on the consumer. Therefore, we think it a matter of
importance that new data on the rate of head louse egg
development at scalp temperature should be obtained.
Since its launch to public sales in January 2006, 4% dimeticone
lotion has become the market leading licensed head louse
treatment in the UK with a share (by value) of 43% (Information
Resources, Inc., 4 weeks to 27
th Jan 2007), fulfilling the initial
estimation that it would appeal to consumers who wished to use
a head louse treatment product free from neurotoxic insecticides
and with no odour. A similar response to the preparation has
occurred in each of the other European countries where the
product is available as a medical device. This has occurred as
a result of public attitude to the preparation rather than
specifically due to clinical evidence recommendations from health
care practitioners as no meta-analysis evaluation has yet been
conducted on the product. Given that most of the evidence for
other active materials is now not only relatively old but also
possibly outdated by the impact of resistance, in the absence of
extensive up to date data it may be difficult to conduct an analysis
of evidence for pediculicides in general that has true clinical
meaning and applicability.
SUPPORTING INFORMATION
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Found at: doi:10.1371/journal.pone.0001127.s001 (0.05 MB
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Found at: doi:10.1371/journal.pone.0001127.s002 (0.28 MB
DOC)
Table S1 Treatment outcome for incorrectly randomised
participants
Found at: doi:10.1371/journal.pone.0001127.s003 (0.03 MB
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Table S2 Analysis of cases of treatment failure following 4%
dimeticone lotion treatment
Found at: doi:10.1371/journal.pone.0001127.s004 (0.04 MB
DOC)
Table S3 Adverse events as recorded on the case report form
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